Infant Bacterial Therapeutics AB Sustainability Reports

Infant Bacterial Therapeutics AB is a clinical-stage pharmaceutical company focused on developing therapies to prevent and treat rare diseases affecting premature infants. Its lead product candidate, IBP-9414, is being developed to prevent necrotizing enterocolitis (NEC) and improve feeding tolerance.

Sector: Manufacturing

Country: Sweden

Exchange: Nasdaq Stockholm

LEI: 2138008KVBXCRJGP6Z26

FIGI: BBG00CB3BRG5

13 reports from 2013 to 2025

• Infant Bacterial Therapeutics AB 2025 Annual Report
• Infant Bacterial Therapeutics AB 2024 Annual Report
• Infant Bacterial Therapeutics AB 2023 Annual Report
• Infant Bacterial Therapeutics AB 2022 Annual Report
• Infant Bacterial Therapeutics AB 2021 Annual Report